Scalper1 News
As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank. In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie’s (ABBV) Viekira Pak and Gilead Sciences’ (GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers. “ABBV has so far nailed Scalper1 News
Scalper1 News